Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK

Bluebird Bio Rails Against Negative Reimbursement Decision

bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.

Gene editiing
NICE take on discounting is 'a threat to gene therapies' • Source: Shutterstock

UK health technology assessment body NICE has published draft guidance rejecting bluebird bio’s gene therapy Zynteglo for routine funding on the National Health Service. The decision making behind the guidance sends a negative signal to investors in gene therapies, warns the company.

Bluebird was “shocked and disappointed by the recommendations,” said Nicola Redfern, bluebird’s UK General Manager.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography